NAICS 325413 - In-Vitro Diagnostic Substance Manufacturing
This U.S. industry comprises establishments primarily engaged in manufacturing in-vitro (i.e., not taken internally) diagnostic substances, such as chemical, biological, or radioactive substances. The substances are used for diagnostic tests that are performed in test tubes, petri dishes, machines, and other diagnostic test-type devices.
Industry trends:
The In-Vitro Diagnostic (IVD) Substance Manufacturing industry (NAICS 325413) is witnessing significant qualitative trends driven by technological advancements, personalized medicine, and shifting healthcare paradigms. One notable trend is the increasing integration of Artificial Intelligence (AI) and machine learning within diagnostic tools, which enhances accuracy, efficiency, and predictive capabilities. Additionally, the rise of molecular diagnostics and genomics is shaping the industry as companies focus on developing tests that provide more specific and actionable insights.
Another trend is the growing emphasis on point-of-care (POC) testing, which offers faster results and greater convenience, particularly in remote and underserved areas. This trend is mirrored by the expansion of at-home testing kits, reflecting a broader movement toward decentralized and patient-centric healthcare. Moreover, the COVID-19 pandemic has accelerated the adoption of digital health and telemedicine solutions, further integrating remote diagnostics into routine care.
In the near future, the IVD industry is expected to see continued growth, fueled by demographic changes such as aging populations and an increasing prevalence of chronic diseases. Regulatory bodies are likely to play a crucial role, with evolving guidelines aimed at ensuring safety and efficacy while fostering innovation. Companies are expected to invest heavily in R&D to develop next-generation diagnostic tools, focusing on areas like liquid biopsy, non-invasive testing, and companion diagnostics, which align with the broader trend toward precision medicine.
The market will also likely experience strategic collaborations and mergers and acquisitions as firms seek to diversify their product portfolios and expand their global presence. Sustainability and ethical considerations may emerge as more prominent factors, influencing both corporate practices and consumer preferences.
This industry is comprised of:
Blood derivative in-vitro diagnostic substances manufacturing
Blood glucose test kits manufacturing
Coagulation in-vitro diagnostic substances manufacturing
Cytology and histology in-vitro diagnostic substances manufacturing
Diagnostic substances, in-vitro, manufacturing
Enzyme and isoenzyme in-vitro diagnostic substances manufacturing
Hematology in-vitro diagnostic substances manufacturing
HIV test kits manufacturing
Hormone in-vitro diagnostic substances manufacturing
In-vitro diagnostic substances manufacturing
Microbiology, virology, and serology in-vitro diagnostic substances manufacturing
Pregnancy test kits manufacturing
Viral in-vitro diagnostic test substances manufacturing
This report includes the ability to segment your Industry by:
- Region
- Employees
- Net Sales
- Company Age
- Total Assets
- Ownership Type
With iCFO You Get
What Is iCFO?
A review and comparison of financial performance of privately-help companies in specified SIC/NAICS industry segment, using industry standard benchmarks.
Sound Business Analysis
Answers come easily with iCFO. Review ROI, sales per employee, profit margins of the top 10%, top 25% and more, to identify areas of concern and opportunity. Examine what if scenarios and P&L impact of reducing costs or adding revenue.
Your Business’ Health In Minutes
It takes only five minutes to enter your data and produce a concise profile of your company’s fiscal state, including critical business ratios focusing on liquidity, profitability, asset efficiency, and growth.